212 related articles for article (PubMed ID: 12506244)
1. [Viral breakthrough in HBeAg-negative chronic hepatitis B patients receiving lamivudine therapy].
Chang YJ; Yim JY; Cho NY; Choi CW; Baek SJ; Ahn SH; Choi DW; Kwon YD; Kim SS; Kwon OS; Kim JH; Yeon JE; Song JW; Byun KS; Lee CH
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):397-404. PubMed ID: 12506244
[TBL] [Abstract][Full Text] [Related]
2. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
3. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
Tsubota A; Arase Y; Suzuki F; Kobayashi M; Matsuda M; Sato J; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
[TBL] [Abstract][Full Text] [Related]
4. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases].
Jeong Id; Park NH; Kim BC; Park JH; Seo KW; Kim DH; Joo KR; Kim DH
Taehan Kan Hakhoe Chi; 2003 Jun; 9(2):69-78. PubMed ID: 12824746
[TBL] [Abstract][Full Text] [Related]
6. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
[TBL] [Abstract][Full Text] [Related]
7. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy.
Kim JH; Yu SK; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Lee CH; Byun KS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1220-5. PubMed ID: 17532786
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B.
Rizzetto M
J Med Virol; 2002 Apr; 66(4):435-51. PubMed ID: 11857520
[TBL] [Abstract][Full Text] [Related]
10. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
[TBL] [Abstract][Full Text] [Related]
12. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
Lok AS; Hussain M; Cursano C; Margotti M; Gramenzi A; Grazi GL; Jovine E; Benardi M; Andreone P
Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
[TBL] [Abstract][Full Text] [Related]
13. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
[TBL] [Abstract][Full Text] [Related]
15. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of lamivudine re-treatment and relapse patterns after initial lamivudine treatment for chronic hepatitis B infection].
Park JH; Park NH; Shin JW; Bang SJ; Kim DH; Joo KR; Kim DH
Taehan Kan Hakhoe Chi; 2003 Sep; 9(3):188-97. PubMed ID: 14515036
[TBL] [Abstract][Full Text] [Related]
17. Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients.
Jang JW; Choi JY; Bae SH; Yoon SK; Kim CW; Nam SW; Lee CD; Lee YS; Cha SB; Chung KW
J Med Virol; 2005 Nov; 77(3):367-73. PubMed ID: 16173025
[TBL] [Abstract][Full Text] [Related]
18. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
[TBL] [Abstract][Full Text] [Related]
19. Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.
Ramezani A; Velayati AA; Roshan MR; Gachkar L; Banifazl M; Keyvani H; Aghakhani A
Int J Infect Dis; 2008 May; 12(3):252-5. PubMed ID: 17954033
[TBL] [Abstract][Full Text] [Related]
20. [Clinical outcome in cases of viral breakthrough during lamivudine therapy in chronic hepatitis B patients].
Ahn SH; Chang YJ; Oh SN; Choi DW; Baek SJ; Jeong WS; Choi CW; Kim KO; Yim HJ; Jo NY; Bak JJ; Kim JS; Bak YT; Lee MS; Yeon JE; Byun KS; Lee CH
Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):389-96. PubMed ID: 12506243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
